Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of candidemia and disseminated candidiasis (including hepatosplenic candidiasis and fungal peritonitis),Treatment of oropharyngeal and esophageal candidiasis,Treatment of vulvovaginal candidiasis (acute and recurrent),Treatment of cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients undergoing chemotherapy or radiation therapy,Off-label: Treatment of coccidioidomycosis, histoplasmosis, blastomycosis, and tinea infections (e.g., tinea pedis, corporis, cruris),Off-label: Prophylaxis of fungal infections in patients with prolonged neutropenia or HIV/AIDS
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. Prolonged in renal impairment (up to 98 hours in creatinine clearance <20 m L/min).
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Primarily hepatic metabolism via cytochrome P450 isoenzymes (CYP2C9, CYP3A4, and to a lesser extent CYP2C19). Fluconazole is a moderate inhibitor of CYP2C9 and CYP3A4 and a weak inhibitor of CYP2C19. Approximately 80% of an administered dose is excreted unchanged in urine; the remainder is excreted as metabolites.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily renal excretion of unchanged drug (~80% of dose). Approximately 11% excreted as metabolites. Biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Plasma protein binding is 11-12%, primarily to albumin. The low binding results in extensive free drug distribution.
Low protein binding; 0–11% bound, primarily to albumin.
Volume of distribution (Vd) is approximately 0.7 L/kg (range 0.5-0.9 L/kg), indicating extensive distribution into total body water and tissues, including penetration into cerebrospinal fluid (CSF), vitreous humor, and peritoneal fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral bioavailability is >90%, essentially complete. Absorption is unaffected by gastric p H or food. Intravenous bioavailability is 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Cr Cl >50 m L/min: no adjustment; Cr Cl 21-50 m L/min: administer 50% of usual dose; Cr Cl 11-20 m L/min: administer 25% of usual dose; intermittent hemodialysis: administer full dose after each dialysis session
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A and B: no adjustment; Child-Pugh Class C: insufficient data, use with caution
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Neonates (0-14 days): 6-12 mg/kg IV every 72 hours; Infants/Children (15 days-1 year): 6-12 mg/kg IV every 24 hours; Children >1 year: 6-12 mg/kg IV every 24 hours; maximum 400 mg/day
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific dose adjustment recommended; monitor renal function and adjust dose based on creatinine clearance due to age-related renal impairment
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Hepatotoxicity: Elevations in liver enzymes have been observed; rare cases of severe hepatic necrosis and fatal hepatic failure have occurred. Discontinue if signs of hepatic injury develop.,QT prolongation: Fluconazole may prolong the QT interval, potentially leading to torsade de pointes. Caution in patients with electrolyte disturbances, bradyarrhythmias, or concurrent use of other QT-prolonging drugs.,Adrenal insufficiency: Cases of reversible adrenal insufficiency have been reported, particularly in patients receiving corticosteroids or those with stress.,Dermatologic reactions: Exfoliative skin disorders (e.g., Stevens-Johnson syndrome) may occur. Discontinue if rash progresses.,Renal impairment: Dose adjustment required in patients with renal dysfunction (Cr Cl <50 m L/min) due to extensive renal elimination.,Pregnancy: Use only if benefit outweighs risk; single-dose therapy for vulvovaginal candidiasis is not recommended during pregnancy.,Lactation: Fluconazole is excreted in human milk; caution in nursing mothers.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to fluconazole or any azole antifungal,Concurrent use of terfenadine (when used at multiple doses of fluconazole ≥400 mg/day) due to risk of serious cardiac arrhythmias,Concurrent use of cisapride due to increased risk of QT prolongation and torsade de pointes,Concurrent use of quinidine, pimozide, or ergot alkaloids (e.g., ergotamine) due to potential for serious adverse effects
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. Avoid alcohol due to potential hepatotoxicity.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous abortion and congenital anomalies (e.g., craniosynostosis, cardiac defects, cleft lip/palate) with prolonged high-dose therapy (≥400 mg/day). Second and third trimesters: low risk at single 150 mg dose; high-dose prolonged use may cause fetal toxicity. Category D for first trimester; Category C for later trimesters.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Fluconazole is excreted into human breast milk with an estimated infant dose of 0.9–3.7% of maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.9–1.0. Single 150 mg dose is considered compatible with breastfeeding. Avoid high-dose prolonged therapy during lactation due to potential infant accumulation and adverse effects (e.g., hepatic toxicity).
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No specific dose adjustment is required for single 150 mg dose for vaginal candidiasis. For systemic infections, use standard dosing (200–400 mg/day) but monitor maternal toxicity and fetal effects. Consider alternative therapy in first trimester. Due to increased volume of distribution and renal clearance in pregnancy, higher doses may be required for life-threatening infections; however, benefit-risk must be evaluated.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Do not use with other fluconazole formulations to avoid dose errors. Monitor renal function and adjust dose in creatinine clearance <50 m L/min. Infuse over 1-2 hours; avoid rapid infusion due to risk of QT prolongation. Check for drug interactions with warfarin, sulfonylureas, phenytoin, and CYP2C9 substrates.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is used to treat fungal infections and is given intravenously.,Report any signs of liver problems (dark urine, yellowing eyes/skin, abdominal pain) or irregular heartbeat immediately.,Avoid alcohol consumption during treatment and for several days after completion.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment early even if you feel better; complete the full course.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% is: 400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.